

A novel strategy for development of glucocorticoids through non-genomic mechanism

Jian Zhou · Min Li · Chun-Quan Sheng ·
Lei Liu · Zhen Li · Yan Wang · Jiang-Rui Zhou ·
Zai-Ping Jing · Yi-Zhang Chen · Chun-Lei Jiang

Received: 22 January 2010/Revised: 28 July 2010/Accepted: 31 August 2010
© Springer Basel AG 2010

Abstract Glucocorticoids (GCs) are routinely believed to take effect through genomic mechanisms, which are also largely responsible for GCs' side effects. Beneficial non-genomic effects of GCs have been reported as being independent of the genomic pathway. Here, we synthesized a new type of GCs, which took effect mainly via

non-genomic mechanisms. Hydrocortisone was conjugated with glycine, lysine and phenylalanine to get a bigger molecular structure, which could hardly go through the cell membrane. Evaluation of the anti-inflammatory efficacy showed that hydrocortisone-conjugated glycine (HG) and lysine could inhibit neutrophil degranulation within 15 min. HG could inhibit IgE-mediated histamine release from mast cells via a non-genomic pathway, and rapidly alleviate allergic reaction. Luciferase reporter assay showed that HG would not activate the glucocorticoid response element within 30 min, which verified the rapid effects independent of the genomic pathway. The work proposes a novel insight into the development of novel GCs, and provides new tools for experimental study on non-genomic mechanisms.

J. Zhou and M. Li contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s00018-010-0526-0) contains supplementary material, which is available to authorized users.

J. Zhou · M. Li · L. Liu · J.-R. Zhou · C.-L. Jiang (✉)
Laboratory of Stress Medicine, Department of Nautical
Medicine, Second Military Medical University,
Shanghai 200433, People's Republic of China
e-mail: cljiang@vip.163.com

J. Zhou · Z.-P. Jing
Department of Vascular Surgery, Changhai Hospital,
Second Military Medical University,
Shanghai 200433, People's Republic of China

C.-Q. Sheng
Department of Medicinal Chemistry, College of Pharmacy,
Second Military Medical University,
Shanghai 200433, People's Republic of China

Z. Li
Department of Clinical Pharmacology, Changhai Hospital,
Second Military Medical University,
Shanghai 200433, People's Republic of China

Y. Wang
Department of Pathophysiology, Second Military Medical
University, Shanghai 200433, People's Republic of China

Y.-Z. Chen
Institute of Neuroscience, Second Military Medical University,
Shanghai 200433, People's Republic of China

Keywords Glucocorticoids · Non-genomic · Neutrophil · Allergy · Mast cells

Abbreviations

GCs	Glucocorticoids
GRE	Glucocorticoid response element
HH	Hydrocortisone
HG	Hydrocortisone-conjugated glycine
HL	Hydrocortisone-conjugated lysine
HP	Hydrocortisone-conjugated phenylalanine
RU486	Mifepristone
ATI	Actidione
fMLP	<i>N</i> -Formyl-methionyl-leucylphenylalanine
MPO	Myeloperoxidase
R_L	Lung resistance
C_{dyn}	Lung dynamic compliance
RBL-2H3 cell	Rat basophilic leukemia mast cell
Boc	Tert-butoxycarbonyl

MMTV-Luc Mouse mammary tumor virus-luciferase
cAMP Cyclic adenosine monophosphate

Introduction

Glucocorticoids (GCs) are widely used in clinical practice, including the management of inflammatory and allergic diseases. Genomic mechanisms of GCs are mediated primarily by the cytosolic glucocorticoid receptors through activation and repression of specific target genes, which normally need several hours to take effect. The ligand-activated receptor dimer activates gene expression by binding to specific DNA sequences (glucocorticoid response element, GRE) in the promoter regions of glucocorticoid-regulated genes, resulting in increased transcription of genes coding for anti-inflammatory proteins, including lipocortin-1 and neutral endopeptidase. In contrast to the regulation of these classical GREs, the repression of target genes is mediated by negative GREs (nGRE), composite GREs or by transrepression. It is assumed that transrepression of transcription factors such as AP-1 and NF-kappa B is the main mechanism by which GCs mediate their anti-inflammatory activity, whereas the side effects of GCs are mainly mediated by GR-DNA-interaction either by activation or by negative regulation of gene expression (reviewed in [1–6]). Administration by inhalation achieves an effective therapy in the airways with a concomitant low risk of unwanted local and systemic effects. However, it still could not eliminate the side effects via the same types of receptors. This discrepancy is the driving force for the intensive search for novel GCs with a better benefit–risk ratio compared to conventional GCs.

In addition to these classical “genomic” mechanisms, there is increasing recognition of alternative modalities of GCs’ action that are independent from modulating gene expression and for this reason defined as “non-genomic”, characterized by a rapid response [7, 8]. We have proposed for the first time that the member receptor-mediated rapid effects of GCs exist on mammalian neurons. Considerable attention has been focused on GCs’ non-genomic mechanisms. It has been reported that GCs could rapidly inhibit Lck and Fyn kinases in human lymphocytes to exert immunosuppressive effects via non-genomic mechanism [9, 10]. Our recent studies have shown that GCs could inhibit degranulation of mast cells and neutrophils, phagocytosis of macrophages via non-genomic mechanism, to exert immunosuppressive, anti-allergic and anti-inflammatory effects [11–14]. However, there have still been few reports about novel drugs based on the knowledge of GCs’ non-genomic effects.

Here, we synthesized a new type of GCs, which excluded the classical genomic effect, by a method of chemical modification of the traditional glucocorticoid molecule. Moreover, non-genomic effects of the new type of GCs on inflammatory and allergic reactions were investigated *in vivo* and *in vitro*. The findings provide a new way of development of novel GCs: traditional glucocorticoid molecule could be chemically modified to exhibit their pharmacological effects via non-genomic mechanisms.

Materials and methods

Structural identification of the new compounds

The ^1H spectra were recorded at 500 MHz with a Bruker instrument, and reported with TMS as internal standard and CDCl_3 as solvent. Chemical shifts (δ values) and coupling constant (J values) were given in ppm and Hz, respectively. ESI mass spectra were performed on an API-3000 LC-MS spectrometer.

Evaluation of degranulation of neutrophils

Isolation of neutrophils

Human neutrophils were isolated from peripheral venous blood of healthy donors, who had not received any medication for at least 2 weeks. By discontinuous percoll gradient technique as previously described [13], the final neutrophils were prepared to >97% purity by Wright’s staining and >97% viable by trypan blue exclusion.

Stimulation of neutrophils

The cells were resuspended in polypropylene tubes at $10^6/\text{ml}$, and stimulated to degranulation by 10^{-6} M *N*-formyl-methionyl-leucylphenylalanine (fMLP) at 37°C . Right after 5 min of stimulation, the tubes were transferred into ice for 3 min and then centrifuged at 800 rpm. The supernatant was rapidly transferred into new tubes and kept at -20°C for marker assays.

Determination of myeloperoxidase release

Myeloperoxidase (MPO) was determined as a marker for neutrophils degranulation by enzymology methods [13, 15]. Assays were carried out in 96-well EIA plates. In each well, 75 μl samples of supernatant were added to an equal volume of TMB (Amresco, USA), kept at room temperature for 15 min and then stopped with 75 μl 0.18 M H_2SO_4 . Optical density (OD) was measured at 450 nm with a reference of 405 nm on an ELx800 microplate reader.

Evaluation of allergic asthma severity

Allergic reaction model

Male Hartley guinea pigs (Second Military Medical University Central Animal Services, China) weighing 200 ± 25 g were sensitized by an injection of 0.5 ml of suspension (5 mg ovalbumin mixed with 50 mg aluminum hydroxide in saline, i.p.) plus 1 ml of suspension (10 mg ovalbumin in saline, i.m.). Then, 30 days later, animals were challenged to allergic asthma reaction with an aerosol of antigen (ovalbumin suspended in saline, 10 mg/ml) for 25 s [12]. In addition, the pulmonary function parameters were monitored continuously. Throughout our experiment, inhalations were performed by a Pari-Master nebulizer (Pari Respiratory Equipment, Germany) via a tracheal cannula. A single model of nebulizer was to control possible differences in drug delivery. All procedures were carried out in accordance with standard guidelines for the care of animals and were approved by the Ethics Committee for Animal Experiments of the Second Military Medical University.

Measurement of lung function

The lung function parameters, lung resistance (R_L) and lung dynamic compliance (C_{dyn}), were measured as previously described [11, 16]. After being anesthetized with urethane (500 mg/kg, i.p.) to maintain abolition of the corneal and withdrawal reflexes, the guinea pig was placed into a whole-body plethysmograph in a supine position. The trachea was cannulated just below the larynx through a tracheotomy, and a pleural cannula was inserted into the right pleural cavity. Tidal volume (V_T) was derived from recordings of plethysmograph pressure detected by a pressure transducer; airflow was measured from a tracheal cannula connected to a pneumotachograph. Transpulmonary pressure was recorded using a second pressure transducer connected between the proximal end of the pleural cannula and the plethysmograph. All signals were recorded on a personal computer by using MedLab5.55 software (Nanjing MedEase Technology, China). R_L and C_{dyn} were calculated from the recordings of volume, flow, and pressure.

Measurement of histamine release from mast cells

Cell culture

The rat basophilic leukemia (RBL-2H3) mast cell line was obtained from Dr. Lin-Zhen Zhang (Changzheng Hospital, China). Monolayer cultures were maintained at 37°C, 5% CO₂ in Dulbecco's modified eagle's medium (Gibco BRL, USA) containing 10% heat-inactivated FBS, 45 mM sodium bicarbonate, and 5 mM L-glucose [17].

Sensitization and stimulation of mast cells

RBL-2H3 mast cells (1×10^5 /ml) were sensitized with 250 ng/ml anti-dinitrophenyl (DNP) IgE at 37°C for 12 h, and the cells were washed to remove excess IgE, and stimulated with antigen (100 ng/ml DNP-HSA) to degranulation at 37°C [18].

Determination of histamine release

Histamine was measured fluorimetrically using the method of Kremzner and Wilson [19, 20]. In the supernatants, *o*-phthaldialdehyde was added directly to the sample after alkalization with 0.4 M NaOH. The same procedure was used for the cells after extraction with 0.1 M HCl. Histamine release was expressed as a percentage of the total amount (remained in the cells plus supernatants). Spontaneous histamine release, less than 5%, was subtracted from all values.

GRE-luciferase reporter assay

Activation of GRE was tested by GRE-luciferase reporter assay as previously described [21]. RBL-2H3 cells were seeded in 24-well culture plates (1×10^5 /well) for 24 h. Cells were transiently transfected with 1 µg of MMTV-luc (Promega, Madison, WI, USA). Normalization of transfection efficiency was done by cotransfection with 1 ng of pRL-TK Renilla reniformis luciferase plasmid (Promega). Then, 12 h after transfection, RBL-2H3 cells were cultured in the medium containing 10% FBS for 24 h, after which they were cultured in the medium supplemented with 5% charcoal-dextran-stripped calf bovine serum containing either 100 nM HH, HG or solvent control for different times. The Dual-Luciferase Reporter assay system (Promega) was used according to the manufacturer's instructions. Data were normalized for transfection efficiency by dividing firefly luciferase activity with that of Renilla luciferase.

Determination of cAMP levels in mast cells

RBL-2H3 mast cells were grown in 96-well plates. Normally, 10^6 cells in 1 ml of medium were seeded in each well and then were sensitized with 250 ng/ml anti-dinitrophenyl (DNP) IgE for 12 h. The cells were washed to remove excess IgE, then incubated with HG (10^{-4} – 10^{-7} M) or control for 7 min before challenge with antigen (100 ng/ml DNP-HSA). The reaction was stopped in ice. Thereafter, the cells were treated with 5% trichloroacetic acid solution, freeze-thawed three times, centrifuged at 3,000 rpm for 15 min, and then the supernatants were collected for cAMP measurements. The cAMP levels were determined by using a cAMP [³H] assay system

(PerkinElmer Life Sciences, MA, USA.), as described in the literature [22].

Acute toxicity studies

Kunming strain mice weighing 18–22 g were individually caged, and observed for health verification for 7 days prior to testing. For intravenous evaluation, five doses of HH, 813.0, 690.0, 588.0, 500.0 and 425.0 mg/kg body weight were administrated to five groups of ten animals (half male and half female) by tail vein injection, respectively. For intramuscular evaluation, five doses of HH, 1060.0, 901.0, 766.0, 651.0 and 535.0 mg/kg body weight were administrated to the five groups of ten animals (half male and half female) by intramuscular injection, respectively. The animals were carefully observed for any toxic effect and distribution of death rate, immediately after dosing, during the subsequent 14 days. At the end of the observational period, the animals were sacrificed by cervical dislocation. A thorough autopsy was carried out on all the animals for pathological examination. Median lethal dose (LD₅₀) and 95% confidence limit were calculated according to the Bliss method [23].

Reagents and chemicals

Salts and other reagents were obtained from Sigma (St Louis, MO, USA) unless otherwise noted. fMLP were dissolved in dimethyl sulfoxide to a final concentration of 50 mM and 2.5 µg/µl, stored at −20°C and diluted in Krebs-Ringer phosphate buffer (KRP, 130 mM NaCl, 5 mM KCl, 1.27 mM MgCl₂, 0.95 mM CaCl₂, 5 mM glucose, 10 mM NaH₂PO₄/Na₂HPO₄, PH 7.4) just before use.

Data analysis

Each experimental point was performed in duplicate, and at least two independent experiments were carried out. Statistical analysis was performed on datasets using SAS software (SAS Institute, NC, USA). The significance of changes in the experimental variables measured was assessed by the *t* test for normally distributed data and the Wilcoxon test for the non-normally distributed data. A two-sided *P* value < 0.05 was considered statistically significant.

Results

Modification on traditional glucocorticoid molecule

As shown in Fig. 1, *N*-tert-butoxycarbonyl-L-glycine (*N*-Boc-L-glycine) was obtained first. Glycine (1.87 g, 0.025 mol) (tert-butoxycarbonyl)₂O (Boc₂O, 10.90 g,





Fig. 1 Schematic presentation of the synthesis of HG. 1 Glycine, 2 *N*-Boc-glycine, 3 *N*-Boc-glycine-21-hydrocortisone-ate, and 4 Glycine-21-hydrocortisone-ate

0.050 mol) and triethylamine aqueous solution (10%, 52 ml, 0.1 mol) were mixed and refluxed for 2.5 h. The reaction mixture was concentrated and the residue was treated with ice water (50 ml). PH value was adjusted to 3 with 1 M HCl. Then, the solution was extracted with ethyl acetate (50 ml × 3) and the organic layer was washed with brine, dried over Na₂SO₄ and concentrated in vacuum, and the residue was crystallized from ether and petroleum (17 ml, 1:8) to get *N*-Boc-L-glycine as white solids (yield 91.7%). Then, *N*-tert-butoxycarbonyl-L-glycine-21-Hydrocortisone-ate (*N*-Boc-glycine-21-hydrocortisone-ate) was synthesized. Hydrocortisone (HH, 3.42 g), *N*-Boc-glycine (1.75 g) and *N,N'*-dicyclohexylcarbodiimide (DCC, 2.15 g) were added to CH₂Cl₂ (100 ml) and stirred for 2 h at room temperature. The reaction mixture was filtered and the filtrate was extracted with ether. The organic layer was washed by 10% HCl and saturated Na₂CO₃, and then was dried over anhydrous MgSO₄. The solvent was removed under reduced pressure and the residue was purified by chromatography on silica gel (hexane: ethyl: acetate, 1:1 and ethyl acetate) to make *N*-Boc-hydrocortisone-21-glycinate as white crystalline powder (4.19 g, 80.6%). *N*-Boc-hydrocortisone-21-glycinate (0.431 g, 0.83 mM) was dissolved in 10 mL CH₂Cl₂ and bubbling anhydrous HCl gas through the solution. The solid was precipitated from solution and removed by filtration. The process was repeated several times until no solid precipitated. The filtrate was crystallized in ether and afforded hydrocortisone-21-glycinate as white powder (0.069 g, 18.4%). Using the same method, hydrocortisone-2-lysine-ate (HL) and hydrocortisone-21-phenylalanine-ate (HP) were synthesized (Fig. 2), with lysine and phenylalanine as vectors, respectively. Structural identification of the



new compounds was performed by $^1\text{H-NMR}$, and detailed data are shown in the Supplemental material.

Primary evaluation of efficacy of the new type of GCs

To get a primary evaluation of the efficacy of the new type of GCs, we studied the rapid effects of the three derivatives on inflammatory reaction, with the model of human neutrophil degranulation. The human neutrophils were preincubated with HP, HL, HG or HH at 10^{-4} M for 7 min before fMLP challenge, respectively. After the cells were stimulated by fMLP for 5 min, the reaction was stopped by ice. Then, the marker of neutrophil degranulation, MPO release, was detected by enzymology methods. Solvent was used as control. The OD value of Control, HP, HL, HG and HH were 0.37 ± 0.05 , 0.28 ± 0.10 , 0.23 ± 0.06 , 0.22 ± 0.05 , and $0.22 \pm 0.07\%$ from four independent experiments performed in duplicate, respectively (Fig. 3). The results showed that HH ($P < 0.05$), HL ($P < 0.05$) and HG ($P < 0.01$) could inhibit fMLP-stimulated MPO release from human neutrophils within 15 min. There was no significant difference among HL, HG and HH groups. We chose HG as the representative of the new type of GCs in the subsequent study.

Rapid effects of HG on allergic asthma reaction in guinea pig

To evaluate the rapid effect of the new type of GCs on allergic reaction, Hartley guinea pigs were administered




Fig. 3 Rapid effects of the new type of GCs on human neutrophil degranulation. HH ($P < 0.05$), HL ($P < 0.05$) and HG ($P < 0.01$) could inhibit fMLP-stimulated MPO release from human neutrophils within 15 min. Data are expressed as means $\pm$ SE of four independent experiments performed in duplicate, * $P < 0.05$, ** $P < 0.01$ in comparison with control group

HG or HH at 3 mg/ml by inhalation for 5 min before challenged to allergic reaction. The lung function parameters, lung resistance (R_L) and dynamic lung compliance (C_{dyn}), were monitored continuously. R_L and C_{dyn} reflected pulmonary function of large airway and small airway, respectively, and the attack of asthma was characterized with the increase of R_L and decrease of C_{dyn} [11, 24]. Moreover, the average maximum changes of R_L (the highest value) and C_{dyn} (the lowest value) were calculated, and expressed as ratios by comparing with R_L and C_{dyn} of the baseline in the same animal before antigen challenge, to evaluate the severity of allergic asthma. Solvent was used as control ($n = 8$). As shown in Table 1, inhaled HG or HH could also significantly inhibit decrease of R_L and increase of C_{dyn} in the asthma model of guinea pig within 10 min ($P < 0.05$). It suggested that the new type of GCs could rapidly inhibit allergic reaction, which precluded

Table 1 Rapid effects of HG on the changes of lung function in allergic reaction

Group	Maximum changes of R_L	Maximum changes of C_{dyn}	n
Control	4.41 ± 0.84	0.37 ± 0.06	8
HH	$3.20 \pm 0.81^*$	$0.60 \pm 0.05^*$	9
HG	$2.31 \pm 0.28^*$	$0.59 \pm 0.05^*$	11

Animals were inhaled HG or HH (3 mg/ml) for 5 min before challenged to allergic asthma by antigen, and solvent used as control. Lung functions were monitored continuously. The average maximum changes of R_L (the highest value) and C_{dyn} (the lowest value) were calculated, and expressed as ratios by comparing with R_L and C_{dyn} of the baseline in the same animal before antigen challenge, to evaluate the allergic asthma severity. Inhaled HG or HH could also significantly inhibited increase of R_L and decrease of C_{dyn} in asthma model of guinea pig within 10 min ($P < 0.05$). There was no significant difference between the HG and HH groups. Data are expressed as means $\pm$ SE

* $P < 0.05$ in comparison with control group

genomic-mediated responses that normally need several hours to occur. There was no significant difference between the HG and HH groups.

Non-genomic effects of HG on histamine release from mast cells

IgE-mediated release of inflammation mediator plays a crucial role in the attack of allergic reaction [25], and we investigated the rapid effects of the new type of GCs on IgE-mediated histamine release from mast cells in vitro. The RBL-2H3 mast cells were sensitized with anti-DNP IgE, and then incubated with HG at concentrations from 10^{-9} to 10^{-6} M for 7 min before antigen challenge. After mast cells were stimulated by antigen for 8 min, the reaction was stopped in ice. Then, histamine release was detected. Solvent was used as control. The histamine release percentage of Control, HG 10^{-9} M, HG 10^{-8} M, HG 10^{-7} M, HG 10^{-6} M and HG 10^{-5} M were 36.09 ± 1.70 , 35.30 ± 1.07 , 34.26 ± 0.73 , 28.00 ± 2.26 , 24.10 ± 1.41 and $21.82 \pm 0.89\%$, respectively, from seven independent experiments (Fig. 4a). The results showed that HG at 10^{-8} – 10^{-5} M could inhibit IgE-mediated histamine release from RBL-2H3 mast cells within 15 min ($P < 0.05$). As the concentration of corticosterone increasing, the percentage of inhibition on histamine release was also gradually enhanced.

To exclude the possibility that the observed effects due to the amino acid residues, we studied whether the glycine itself could inhibit histamine release of mast cells. The sensitized RBL-2H3 mast cells were incubated with HG, HH, or glycine at 10^{-7} M for 7 min before antigen challenge. Solvent was used as control. As shown in Fig. 4b, Both HG and HH could inhibit antigen-induced histamine release of mast cells within 15 min. Moreover, the rapid inhibition was not found in the glycine-pretreated group, which excluded the possibility that the observed effects are due to the amino acid residues.

We carried out a second series of experiments to assess the non-genomic mechanism involved in the GCs' rapid effects. Mifepristone (RU486) is an antagonist of classic glucocorticoid receptor, which could exclude the traditional genomic mechanism mediated by glucocorticoid receptor [12, 26, 27]. The sensitized cells were preincubated with RU486 at 10^{-6} M for 30 min, and then incubated with HG (10^{-7} M) for 7 min before antigen was added. Solvent was used as control. The histamine release percentage of Control, RU, HG, and HG + RU were 33.51 ± 0.88 , 32.92 ± 1.59 , 24.45 ± 0.92 and $24.46 \pm 1.04\%$, respectively, from seven independent experiments performed in duplicate (Fig. 4c). The results showed that RU486 could not block the rapid inhibitory

effect of HG on IgE-mediated histamine release from mast cells. It suggested that glucocorticoid receptor pathway was not involved in rapid effects of the new type of GCs.

To confirm the non-genomic mechanisms involved in the effects of HG, we studied the influence of actidione (ATI) on the rapid effect of HG. ATI is the protein synthesis inhibitor, which could block the protein synthesis by genomic mechanism pathway [8, 26, 28]. The sensitized cells were preincubated with ATI (10^{-4} M) for 3 h, and then incubated with HG (10^{-7} M) for 7 min before antigen added. Solvent was used as control. The histamine release percentage of Control, ATI, HG, and HG + ATI were 34.31 ± 1.51 , 33.23 ± 1.42 , 25.06 ± 1.61 , and $25.08 \pm 1.10\%$, respectively, from seven independent experiments performed in duplicate (Fig. 4d). The results showed that ATI could not block the rapid inhibitory effects of HG on IgE-mediated histamine release from mast cells. It suggested that the rapid effect of the new type of GCs was independent from the protein synthesis, which verified the existence of the non-genomic mechanism.

We further examined the time-course of HG's effect. The sensitized cells were incubated with HG (10^{-7} M) for various times before antigen was added. The histamine release percentage of GCs' incubation by 1, 7, 15, 30 min, 2 h and Control were 32.75 ± 1.33 , 28.08 ± 0.91 , 25.06 ± 0.76 , 27.95 ± 0.89 , 33.06 ± 0.45 , and $34.25 \pm 0.72\%$, respectively, from seven independent experiments performed in duplicate (Fig. 4e). A significant decrease of histamine release was detected from 7 min of GCs' incubation, and peaked at 15 min. However, HG's inhibition decreased with 30 min incubation, and was weaker with 2 h incubation.

Rapid effect of HG was not mediated by classical GR pathway

GRE-luciferase reporter assay was widely used to assess the activation of the classical glucocorticoid receptor pathway. To check whether HG act via genomic mechanisms, we determined the activation of GRE by GRE-luciferase reporter assay. The sensitized RBL-2H3 cells were treated with 10^{-7} M HH and HG at various times. Solvent was used as control. At 7, 15 and 30 min, the induction of GRE-luciferase expression by HH were 1.00 ± 0.24 , 1.32 ± 0.11 , 1.40 ± 0.23 , 0.93 ± 0.14 , and by HG were 0.95 ± 0.03 , 0.98 ± 0.08 , 0.96 ± 0.11 , 0.93 ± 0.14 , respectively, (Fig. 5). The result showed that GRE could be partly activated by HH from 15 min, and the activation was not found in HG for 30 min, which verified that HG's rapid effects were independent of classical glucocorticoid receptor pathway.




Fig. 4 Non-genomic effects of HG on histamine release from mast cells. **a** Dose-response curve of HG's rapid inhibition on histamine release of mast cells. HG could inhibit histamine release in dose-dependent manner within 15 min. **b** Summary of histamine release percentage of *Control*, *HG* (10^{-7} M), *HH* (10^{-7} M), and *Gly* (10^{-7} M). Glycine could not inhibit the histamine release itself. **c** Summary of histamine release percentage of *Control*, *HG* (10^{-7} M), *RU* (RU486, 10^{-6} M), and *HG* (10^{-7} M) + *RU* (10^{-6} M). RU486

could not block the rapid inhibitory effects of HG. **d** Summary of histamine release percentage of *Control*, *ATI* (Actidione, 10^{-4} M), *HG* (10^{-7} M), and *HG* (10^{-7} M) + *ATI* (10^{-4} M). Actidione could not block the rapid inhibitory effects of HG. **e** Time-course curve of HG's inhibition on histamine release. Data are expressed as means $\pm$ SD of histamine release percentage. * $P < 0.05$, ** $P < 0.01$ in comparison with control group

cAMP was not involved in the rapid effect of HG on mast cells

cAMP is also an important second messenger involved in the degranulation of mast cells. We also studied the rapid effect of HG on intracellular cAMP levels in mast cells. The sensitized RBL-2H3 mast cells were incubated with HG at concentrations from 10^{-7} to 10^{-4} M for 7 min before antigen challenge. Solvent was used as control. As shown in

Fig. 6, there was no significant difference in cAMP levels between HG (10^{-4} – 10^{-7} M) pretreatment and control group. It suggested that cAMP was not the key signal in the GCs' rapid effect on degranulation of mast cells.

Acute toxicity studies

We examined the safety profile of HG in further detail. The acute toxicity evaluation in mice showed that there was a




Fig. 5 Rapid effect of HG and HH on activation of GRE. RBL-2H3 cells (1×10^5) were transiently co-transfected with 1 μ g MMTV-Luc, 1 ng of pRL-TK Renilla reniformis luciferase plasmid as control. Transfected cells were treated with or without 100 nM HH, HG or solvent control for 7, 15 and 30 min. The ratios of firefly to *R. reniformis* Luc activities were calculated to correct for differences in transfection efficiency. The average ratio of the untreated control group was used to calculate the percentage of change in the reporter activity of treated groups, and results are expressed as the mean $\pm$ SD ($n = 3$ each). HH ** $P < 0.01$ in comparison with control group




Fig. 6 Influence of HG on intracellular cAMP levels in mast cells. The sensitized mast cells were incubated with 10^{-4} – 10^{-7} M HG or solvent control for 7 min at 37°C, and then the reaction was terminated by ice-bath. The cAMP levels were measured by using a cAMP [^{3} H] assay system. Data are expressed as means $\pm$ SD ($n = 5$ each)

regular dose-dependent increase in mortality in both sexes of mice after administration. In addition to death, the toxicities included hair-floppy, inactivity and loss of weight. The autopsy of the treated animals did not reveal any macroscopic changes in major organ, such as heart, liver, spleen, lung and kidney. As shown in Fig. 7, the LD₅₀ value and 95% confidence limits of HG administrated by i.v. and i.m.




Fig. 7 Acute toxicity studies of HG on mice by i.v. and i.m. Groups of 10 mice each were administrated with different concentrations of HG by i.v. and i.m. The calculated median lethal dose (LD₅₀) were 567.8 mg/kg and 776.5 mg/kg, respectively

were calculated as 567.8 (518.3–621.9) mg/kg and 776.5 (710.1–849.1) mg/kg, respectively, which indicated that HG was a compound with low toxicity.

Discussion

GCs are potent anti-inflammatory and immunosuppressant agents available. Over the past six decades, it has been widely assumed that GCs work solely through regulating gene expression. Nowadays, the non-genomic mechanism of GCs' rapid action has attracted more and more attention [29–32]. It is clear that GCs can modulate immune reaction, neuronal excitability, behavior and so on, within seconds or minutes via non-genomic pathways. The non-genomic effects could be mediated by at least three mechanisms: (1) physicochemical interactions with cellular membranes (non-specific non-genomic effects); (2) cytosolic glucocorticoid receptor (cGCR)-mediated non-genomic effects; and (3) membrane-bound glucocorticoid receptor (mGCR)-mediated non-genomic effects [33–37]. We have reported that, in neurons and pituitary cells, GCs might act on putative membrane receptors, via the PTX-sensitive-G protein-PKC pathway and the PKA pathway to induce a variety of intracellular responses [38, 39].

Beneficial rapid non-genomic effects of glucocorticoid have been reported in the treatment of allergic disease. Tillmann reported acute non-genomic action of GCs in seasonal allergic rhinitis [40]. Rapid effects of GCs on immune reaction via non-genomic mechanism provide us with a new strategy for development of novel drugs [41]. Here, we propose a new approach to development of novel GCs: a traditional glucocorticoid molecule is conjugated to

a macromolecule to exclude the classical genomic effect and retain the rapid non-genomic effect.

As one of the typical representatives of GCs-conjugated macromolecule, corticosterone-conjugated bovine-serum albumin (GC-BSA) has been used as a useful tool for studying non-genomic effects, which could mimic the rapid effects of GCs but could not go through the cell membrane [31, 32]. Nevertheless, GC-BSA has too high a molecular weight and too low solubility, and therefore could be used only in experimental studies but not as clinical drugs. In this study, we chose amino acids conjugated with GCs to make the products more soluble with a bigger molecular structure. In addition, amino acids as vector might ameliorate absorption, distribution, and excretion of the products. With the glycine, lysine and phenylalanine as vector, we got three new compounds: HG, HL, and HP.

To get a primary evaluation of efficacy of the new type of GCs, the rapid effects on inflammatory reaction were studied after structure identification. The results showed that HG and HL could rapidly inhibit release of inflammatory mediator from human neutrophils. Moreover, we investigated rapid non-genomic effects of HG on allergic reaction in vivo and in vitro. HG could inhibit IgE-mediated histamine release from mast cells via non-genomic pathway, and rapidly alleviate allergic asthma reaction in animal models. RU486 could not block HG's rapid inhibition on histamine release from mast cells, and activation of GRE was not found by HG for 30 min, which suggested that HG's rapid effect was not mediated by classical glucocorticoid receptor pathway. It was vital to clarify the signal transduction pathway involved in GCs' rapid effect. Our previous studies have shown that GCs could significantly inhibit the raise of $[Ca^{2+}]_i$ induced by antigen and cause a similar degree of reduction in exocytosis. By the employment of well-controlled Ca^{2+} stimulation generated by intracellular photolysis of caged- Ca^{2+} , we verified modulation of Ca^{2+} signaling might play an key role in the non-genomic action of GCs [12]. Regrettably, the study showed that cAMP was not involved in the rapid effect of the novel GCs (HG). Further study on other signals in activation of mast cells (such as Syk) would provide more information on the non-genomic mechanism.

In our experiment, the novel GCs could take non-genomic effects at the minimum concentration 10^{-8} M (Fig. 4a), which is close to the GCs' physiological concentration in stress in vivo [42, 43]. It indicates that GCs' non-genomic effects might play an important role in modulating stress and immune response. In addition, the minimum concentration was quite low as compared to the LD_{50} value, about 1.46×10^{-2} M in molar terms, which is estimated from the weight per kg of acute toxicity assays (567.8 mg/kg) and the estimated blood volume per kg of

mice [44] and molecular weight of HG (457.0). It also indicates that the novel GCs are relevant for possible use as drugs. Pharmacokinetics studies of the novel GCs are ongoing in our laboratory to give more information on a new formulation for treatment.

The work proposes novel insight into the development of GCs, and the synthesized derivatives, GCs conjugated amino acids, also provide us with new tools for experimental study on non-genomic mechanisms, which have better solubility compared with previous reagents. The new type of GCs is very promising as a prodrug; however, many questions remain. The huge potential of them in reducing the systemic side effects has not been fully investigated. Further studies might raise the possibility of new therapeutic strategies for inflammatory and allergic diseases.

Acknowledgment The work was supported by grants from National Natural Science Foundation of China (30873077 and 30700344), Shanghai Basic Research Foundation (08JC1404900), Natural Science and Technology Major Project (2009ZX09303002), and Mental Health Program (2010).

References

1. Baschant U, Tuckermann J (2010) The role of the glucocorticoid receptor in inflammation and immunity. *J Steroid Biochem Mol Biol* 120:69–75
2. De Bosscher K, Haegeman G (2009) Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. *Mol Endocrinol* 23:281–291
3. Stahn C, Buttgerit F (2008) Genomic and nongenomic effects of glucocorticoids. *Nat Clin Pract Rheumatol* 4:525–533
4. Dostert A, Heinzel T (2004) Negative glucocorticoid receptor response elements and their role in glucocorticoid action. *Curr Pharm Des* 10:2807–2816
5. De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor- κ B or activator protein-1: molecular mechanisms for gene repression. *Endocr Rev* 24:488–522
6. Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. *Clin Sci (Lond)* 94:557–572
7. Lipworth BJ (2000) Therapeutic implications of non-genomic glucocorticoid activity. *Lancet* 356:87–89
8. Lose R, Wehling M (2003) Nongenomic actions of steroid hormones. *Nat Rev Mol Cell Biol* 4:46–56
9. Hua SY, Chen YZ (1989) Membrane receptor-mediated electrophysiological effects of glucocorticoid on mammalian neurons. *Endocrinology* 124:687–691
10. Löwenberg M, Tuynman J, Bilderbeek J, Gaber T, Buttgerit F, van Deventer S, Peppelenbosch M, Hommes D (2005) Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. *Blood* 106:1703–1710
11. Zhou J, Kang ZM, Xie QM, Liu C, Lou SJ, Chen YZ, Jiang CL (2003) Rapid nongenomic effects of glucocorticoids on allergic asthma reaction in the guinea pig. *J Endocrinol* 177:R1–R4
12. Zhou J, Liu DF, Liu C, Kang ZM, Shen XH, Chen YZ, Xu T, Jiang CL (2008) Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. *Allergy* 63:1177–1185

13. Liu L, Wang YX, Zhou J, Long F, Sun HW, Liu Y, Chen YZ, Jiang CL (2005) Rapid non-genomic inhibitory effects of glucocorticoids on human neutrophil degranulation. *Inflamm Res* 54:37–41
14. Long F, Wang YX, Liu L, Zhou J, Cui RY, Jiang CL (2005) Rapid nongenomic inhibitory effects of glucocorticoids on phagocytosis and superoxide anion production by macrophages. *Steroids* 70:55–61
15. Borregaard N, Cowland JB (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. *Blood* 89:3503–3521
16. Laude EA, Emery CJ, Suvarna SK, Morcos SK (1999) The effect of antihistamine, endothelin antagonist and corticosteroid prophylaxis on contrast media induced bronchospasm. *Br J Radiol* 72:1058–1063
17. Arthur JF, Shen Y, Kahn ML, Berndt MC, Andrews RK, Gardiner EE (2007) Ligand binding rapidly induces disulfide-dependent dimerization of glycoprotein VI on the platelet plasma membrane. *J Biol Chem* 282:30434–30441
18. Jolly PS, Bektas M, Watterson KR, Sankala H, Payne SG, Milstien S, Spiegel S (2005) Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing SIP receptors. *Blood* 105:4736–4742
19. Liu C, Zhou J, Zhang LD, Wang YX, Kang ZM, Chen YZ, Jiang CL (2007) Rapid inhibitory effect of corticosterone on histamine release from rat peritoneal mast cells. *Horm Metab Res* 39:273–277
20. Kremzner LT, Wilson IB (1961) A procedure for the determination of histamine. *Biochim Biophys Acta* 50:365–367
21. Chen YX, Li ZB, Diao F, Cao DM, Fu CC, Lu J (2007) Up-regulation of RhoB by glucocorticoids and its effects on the cell proliferation and NF-kappaB transcriptional activity. *J Steroid Biochem Mol Biol* 101:179–187
22. Choi YH, Yan GH, Chai OH, Zhang X, Lim JM, Kim JH, Lee MS, Han EH, Kim HT, Song CH (2006) Inhibitory effects of *Agaricus blazei* on mast cell-mediated anaphylaxis-like reactions. *Biol Pharm Bull* 29:1366–1371
23. Bliss CI (1934) The method of probits. *Science* 79:38–39
24. Xie QM, Zeng LH, Zheng YX, Lu YB, Yang QH (1999) Bronchodilating effects of bambuterol on bronchoconstriction in guinea pigs. *Zhongguo Yao Li Xue Bao* 20:651–654
25. Broide D (2008) New perspectives on mechanisms underlying chronic allergic inflammation and asthma in 2007. *J Allergy Clin Immunol* 122:475–480
26. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. *Nat Med* 8:473–479
27. Long F, Wang Y, Qi HH, Zhou X, Jin XQ (2008) Rapid non-genomic effects of glucocorticoids on oxidative stress in a guinea pig model of asthma. *Respirology* 13:227–232
28. Roy B, Rai U (2009) Genomic and non-genomic effect of cortisol on phagocytosis in freshwater teleost *Channa punctatus*: an in vitro study. *Steroids* 74:449–455
29. Di S, Maxson MM, Franco A, Tasker JG (2009) Glucocorticoids regulate glutamate and GABA synapse-specific retrograde transmission via divergent nongenomic signaling pathways. *J Neurosci* 29:393–401
30. Ghosh MC, Baatar D, Collins G, Carter A, Indig F, Biragyn A, Taub DD (2009) Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck. *Blood* 113:575–584
31. Borski RJ (2000) Nongenomic membrane actions of glucocorticoids in vertebrates. *Trends Endocrinol Metab* 11:427–436
32. Di S, Malcher-Lopes R, Halmos KC, Tasker JG (2003) Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. *J Neurosci* 23:4850–4857
33. Maier C, Rünzler D, Schindelar J, Grabner G, Waldhäusl W, Köhler G, Luger A (2005) G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. *J Cell Sci* 118:3353–3361
34. Buttgerit F, Scheffold A (2002) Rapid glucocorticoid effects on immune cells. *Steroids* 67:529–534
35. Croxtall JD, Choudhury Q, Flower RJ (2000) Glucocorticoids act within minutes to inhibit recruitment of signalling actors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. *Br J Pharmacol* 130:289–298
36. Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, Bienert M, Radbruch A, Burmester GR, Lauster R, Scheffold A, Buttgerit F (2004) Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. *FASEB J* 18:70–80
37. Song IH, Buttgerit F (2006) Non-genomic glucocorticoid effects to provide the basis for new drug developments. *Mol Cell Endocrinol* 246:142–146
38. Qiu J, Wang CG, Huang XY, Chen YZ (2003) Nongenomic mechanism of glucocorticoid inhibition of bradykinin-induced calcium influx in PC12 cells: possible involvement of protein kinase C. *Life Sci* 72:2533–2542
39. Chen YZ, Qiu J (1999) Pleiotropic signaling pathways in rapid, nongenomic action of glucocorticoid. *Mol Cell Biol Res Commun* 2:145–149
40. Tillmann HC, Stuck BA, Feuring M, Rossol-Haseroth K, Tran BM, Lösel R, Schmidt BM, Hörmann K, Wehling M, Schultz A (2004) Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. *Eur J Clin Invest* 34:67–73
41. Löwenberg M, Stahn C, Hommes DW, Buttgerit F (2008) Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. *Steroids* 73:1025–1029
42. Jones MT, Hillhouse EW, Burden JL (1977) Dynamics and mechanics of corticosteroid feedback at the hypothalamus and anterior pituitary gland. *J Endocrinol* 73:405–417
43. Yeh KY (1984) Corticosterone concentrations in the serum and milk of lactating rats: parallel changes after induced stress. *Endocrinology* 115:1364–1370
44. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. *Pharm Res* 10:1093–1095